Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA(®)): a randomized, double-blind, placebo-controlled clinical trial in patients with type 2 diabetes and high cardio-renal risk

BACKGROUND: Cardiovascular (CV) outcome trials in type 2 diabetes (T2D) have underrepresented patients with chronic kidney disease (CKD), leading to uncertainty regarding their kidney efficacy and safety. The CARMELINA(®) trial aims to evaluate the effects of linagliptin, a DPP-4 inhibitor, on both...

Descripción completa

Detalles Bibliográficos
Autores principales: Rosenstock, Julio, Perkovic, Vlado, Alexander, John H., Cooper, Mark E., Marx, Nikolaus, Pencina, Michael J., Toto, Robert D., Wanner, Christoph, Zinman, Bernard, Baanstra, David, Pfarr, Egon, Mattheus, Michaela, Broedl, Uli C., Woerle, Hans-Juergen, George, Jyothis T., von Eynatten, Maximilian, McGuire, Darren K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5870815/
https://www.ncbi.nlm.nih.gov/pubmed/29540217
http://dx.doi.org/10.1186/s12933-018-0682-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5870815/
https://www.ncbi.nlm.nih.gov/pubmed/29540217
http://dx.doi.org/10.1186/s12933-018-0682-3

Ejemplares similares